22 May 2013
Keywords: enrolment, complete, ph, iii, trial, aspreva/roche, cellcept
Article | 05 December 2005
Canadian drugmaker Aspreva has completed enrollment of 176 patients in a Phase III clinical study to assess the safety and efficacy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 December 2005
21 May 2013
© 2013 thepharmaletter.com